BTG's Plevitrexed Shows Promising Efficacy and Tolerability in a Phase I/II study
24-Jan-2007 -
BTG plc announced the successful outcome of a Phase I/II study of plevitrexed, a selective inhibitor of thymidylate synthase targeting gastric, pancreatic and ovarian cancer. The study, presented at the ASCO 2007 Gastrointestinal Cancers Symposium in Orlando, Florida was designed to investigate ...
cisplatin
dosing
gastric cancer
+5